siRNA-targeted inhibition of growth hormone receptor in human colon cancer SW480 cells

Table 1 Weight changes of tumor-bearing mice (n = 6; mean ± SD)

	Weight (g, mean ± SD)
Time	NS	G2	GH	FU	FU+G2	G2+FU+GH
Pre-operation	20.69 ± 0.67	21.92 ± 0.70	20.67 ± 0.57	21.93 ± 0.58	21.86 ± 0.73	21.25 ± 0.79
Inoculation 2 d	20.64 ± 0.60	21.86 ± 0.79	20.82 ± 0.56	20.89 ± 0.661	20.09 ± 0.5513	20.41 ± 0.8513
Inoculation 5 d	20.65 ± 0.49	21.56 ± 0.81	20.96 ± 0.541	20.94 ± 0.671	19.92 ± 0.58135	20.42 ± 0.761
Inoculation 8 d	20.65 ± 0.65	21.53 ± 0.561	21.18 ± 0.441	20.41 ± 0.7313	19.92 ± 0.521235	20.53 ± 0.7013
Inoculation 11 d	20.67 ± 0.63	21.53 ± 0.731	21.27 ± 0.5314	19.86 ± 0.5713	20.06 ± 0.521235	20.63 ± 0.8115
Inoculation 14 d	20.61 ± 0.62	21.60 ± 0.6812	21.51 ± 0.4414	9.46 ± 0.52123	19.86 ± 0.9212	20.86 ± 0.7214
Inoculation 17 d	20.68 ± 0.66	21.60 ± 0.711	21.64 ± 0.45124	18.94 ± 0.47123	19.40 ± 0.60123	21.04 ± 0.7814

¹Compared with pre-operation, P < 0.05;

²Compared with NS group, P < 0.05;

³Compared with G₂ group, P < 0.05;

⁴Compared with FU group, P < 0.05;

⁵Compared with GH group, P < 0.05. NS: Normal saline; G₂: Recombinant plasmid; GH: Growth hormone; FU: 5-fluorouracil.